AI English summary of an SEC filing — figures as filed
HCA Healthcare HCAThe company said revenues for Q1 2025 totaled $18.321 billion ($17.339 billion a year earlier), and net income attributable to HCA Healthcare, Inc. totaled $1.610 billion, or $6.45 per diluted share. Adjusted EBITDA was $3.733 billion, and net income for the year-earlier period included gains on sales of facilities of $201 million.
Key points
AI summaryThe company said revenues for Q1 2025 totaled $18.321 billion ($17.339 billion a year earlier), and net income attributable to HCA Healthcare, Inc. totaled $1.610 billion, or $6.45 per diluted share. Adjusted EBITDA was $3.733 billion, and net income for the year-earlier period included gains on sales of facilities of $201 million.
HCA Healthcare said cash flows from operating activities totaled $1.651 billion for Q1 2025, compared with $2.469 billion a year earlier. It repurchased 7.762 million shares of common stock at a cost of $2.506 billion during the same quarter, and the remaining repurchase authorization was $8.259 billion as of March 31.
The company said same facility admissions rose 2.6% and same facility equivalent admissions rose 2.8% in Q1 2025. Same facility emergency room visits increased 4.0%, same facility outpatient surgeries declined 2.1%, and same facility revenue per equivalent admission increased 2.9%.
The company said its Board of Directors declared a quarterly cash dividend of $0.72 per share, payable on June 30, 2025. Separately, HCA Healthcare reaffirmed its full-year guidance ranges issued as of January 24, 2025, with full-year revenue guidance of $72,800 million to $75,800 million.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Q1 Revenues, Net Income and Adjusted EBITDA
The company said revenues for Q1 2025 totaled $18.321 billion ($17.339 billion a year earlier), and net income attributable to HCA Healthcare, Inc. totaled $1.610 billion, or $6.45 per diluted share. Adjusted EBITDA was $3.733 billion, and net income for the year-earlier period included gains on sales of facilities of $201 million.
Source · Based on the filing body and exhibits
Q1 Operating Cash Flow and Share Repurchases
HCA Healthcare said cash flows from operating activities totaled $1.651 billion for Q1 2025, compared with $2.469 billion a year earlier. It repurchased 7.762 million shares of common stock at a cost of $2.506 billion during the same quarter, and the remaining repurchase authorization was $8.259 billion as of March 31.
Source · Based on the filing body and exhibits
Same Facility Admissions and Revenue per Admission Metrics
The company said same facility admissions rose 2.6% and same facility equivalent admissions rose 2.8% in Q1 2025. Same facility emergency room visits increased 4.0%, same facility outpatient surgeries declined 2.1%, and same facility revenue per equivalent admission increased 2.9%.
Source · Based on the filing body and exhibits
Quarterly Dividend and Reaffirmed 2025 Guidance
The company said its Board of Directors declared a quarterly cash dividend of $0.72 per share, payable on June 30, 2025. Separately, HCA Healthcare reaffirmed its full-year guidance ranges issued as of January 24, 2025, with full-year revenue guidance of $72,800 million to $75,800 million.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…